Ota K
Drugs Exp Clin Res. 1985;11(1):17-21.
Single agent activity of aclacinomycin A or aclarubicin (ACR) for acute leukaemia in adults was as follows: complete remission was achieved in 8 of 21 (38%) with untreated patients and 7 of 41 (17%) with prior chemotherapy; thus the overall complete remission rate was 24%. The optimal dose schedule was 14 mg/m2/d daily i.v. administration, and a median total dose of 200 mg/m2 and 16 days were necessary for induction of complete remission. In combination, with behenoyl ara-C, ACR, 6-mercaptopurine and prednisolone, complete remission was achieved in 40 of 60 (67%) previously untreated patients, and 41 of 65 (63%) with prior chemotherapy; thus the overall rate was 65%. In a phase II study of ACR for solid tumours, response was achieved in carcinoma of oesophagus (1/3), stomach (12/84, 14%), gall bladder (1/4), pancreas (1/8), lung (4/30, 13%), breast (6/33, 18%), uterus (1/4), ovary (3/9, 33%), head and neck (1/5) and sarcoma (1/5). Side-effects of ACR most frequently observed were nausea and vomiting (around 30%) and a moderate grade marrow suppression was noted. An ECG change was observed in 7%, but there were no cases of chronic heart failure.
阿克拉霉素A或阿柔比星（ACR）对成人急性白血病的单药活性如下：未治疗患者中21例有8例（38%）达到完全缓解，接受过前期化疗的41例中有7例（17%）达到完全缓解；因此总体完全缓解率为24%。最佳剂量方案是每日静脉注射14mg/m²，诱导完全缓解需要的中位总剂量为200mg/m²，疗程为16天。与山嵛酰阿糖胞苷、ACR、6-巯基嘌呤和泼尼松龙联合使用时，60例先前未治疗的患者中有40例（67%）达到完全缓解，65例接受过前期化疗的患者中有41例（63%）达到完全缓解；因此总体缓解率为65%。在一项ACR用于实体瘤的II期研究中，食管癌（1/3）、胃癌（12/84，14%）、胆囊癌（1/4）、胰腺癌（1/8）、肺癌（4/30，13%）、乳腺癌（6/33，18%）、子宫癌（1/4）、卵巢癌（3/9，33%）、头颈癌（1/5）和肉瘤（1/5）出现缓解。最常观察到的ACR副作用是恶心和呕吐（约30%），并观察到中度骨髓抑制。7%的患者出现心电图改变，但无慢性心力衰竭病例。
